Efficacy and immune-related adverse events of pembrolizumab with bone-modifying agents in female patients with breast cancer

By afschroeder • June 25, 2025

LeVee A, Peluso E, Lechner MG, Ruel N, Mortimer J, Kang I, Tsai K. Efficacy and immune-related adverse events of pembrolizumab with bone-modifying agents in female patients with breast cancer. Oncologist. 2025 Jun 4;30(6):oyaf134. doi: 10.1093/oncolo/oyaf134. PMID: 40549044.

Tags: breast cancer, Denosumab, Endocrinology, immune-related adverse events, immunotherapy, pembrolizumab, Publications

Related Posts

Oxidative stress-regulatory role of miR-10b-5p in the diabetic human cornea revealed through integrated multi-omics analysis

Zha D, Gamez J, Ebrahimi SM, Wang Y, Verma N, Poe AJ, White S, Shah R, Kramerov AA, Sawant OB, Santiskulvong C, Stotland AB, Wang[...]

The gut microbiome promotes mitochondrial respiration in the brain of a Parkinson’s disease mouse model

Morais LH, Stiles L, Freeman M, Oguienko AD, Hoang JD, Ji J, Jones J, Quan B, Devine J, Bois JS, Chou TF, Trinh J, Picard[...]

Consensus-based disease definitions for endocrine immune-related adverse events of immune checkpoint inhibitors

Zhu L, Cheung YM, Chiang C, Gallagher EJ, Hamnvik OR, Mammen J, Quandt Z, Jones R, McDunn J, Al-Bahadili H, Angell T, Bancos I, Betof[...]